Late Stage Chronic Kidney Disease Drugs Market Scope And Analysis

Report Code : TIPRE00013768
Category : Life Sciences

No. of Pages : 150

Buy Now

Late Stage Chronic Kidney Disease Drugs Market Analysis, Scope, and Growth by 2031

Buy Now

Late Stage Chronic Kidney Disease Drugs Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 5.74 Billion
Market Size by 2031	US$ 17.95 Billion
Global CAGR (2023 - 2031)	12.2%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Type Potassium Binders Calcimimetics Calcium-Based Phosphate Binders Vitamin D Sterols By Indication Late Stage Chronic Kidney Disease Induced Hyperphosphatemia Late Stage Chronic Kidney Disease Induced Hyperparathyroidism Late Stage Chronic Kidney Disease Induced Hyperkalaemia By Distribution Channel Online Pharmacies Hospital Pharmacies Retail Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	AbbVie Inc Amgen AstraZeneca Sanofi Kyowa Kirin Co Ltd Takeda Pharmaceutical Company Limited Astellas Pharma Inc Bayer AG Vifor Pharma Management Ltd Akebia Drugs Inc

Late Stage Chronic Kidney Disease Drugs Market News and Recent Developments

The Late Stage Chronic Kidney Disease Drugs market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Late Stage Chronic Kidney Disease Drugs:

Sun Pharma and Bayer jointly agreed to market a drug for treating chronic kidney disease. Under the terms of the agreement, Bayer has granted Sun Pharma non-exclusive rights to market and distribute a second Finerenone product under the brand name Lyvelsa. (Bayer /Press Release, January 2024)
Boehringer Ingelheim with Eli Lilly and Company announced FDA approval for Jardiance (empagliflozin) tablets, examined as a potential treatment to reduce the risk of kidney disease development and cardiovascular death in adults with chronic kidney disease (CKD). (Source: Boehringer Ingelheim International GmbH, Press Release, October 2023)

Late Stage Chronic Kidney Disease Drugs Market Report Coverage and Deliverables

The “Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles